share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K：SERA 预测报告了 2024 年第二季度财务业绩
美股SEC公告 ·  2024/08/08 04:19

Moomoo AI 已提取核心信息

Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
Sera Prognostics reported Q2 2024 revenue of $24,000, down from $123,000 in Q2 2023. The company achieved a 20% reduction in total operating expenses to $9.3 million, leading to a narrower net loss of $8.3 million compared to $10.5 million year-over-year. Research and development expenses increased 19% to $4.4 million, while selling, general and administrative costs decreased 38% to $4.9 million.The company highlighted recent achievements including the publication of positive AVERT PRETERM TRIAL results and conditional approval from New York State for ambient whole-blood collection. The final PRIME study database lock is anticipated by mid-September, with publication targeted for spring pregnancy conferences.Management is executing various cost-effective programs to educate physicians and patients about their PreTRM® Test, including partnerships with medical professional platforms and multi-channel marketing strategies. The company maintains focus on building evidence portfolio and establishing care guidelines to drive adoption and revenue growth.
Sera Prognostics报告2024年第二季度营业收入为24,000美元，较2023年第二季度的123,000美元下降。公司实现了营业费用减少20%，降至930万，导致净亏损收窄至830万，同比相比于1050万。研究与开发费用增加19%，达到440万，而销售、一般及行政费用减少38%，降至490万。公司强调最近的成就，包括正面结果的AVERt PRETERm试验报告以及来自纽约州的环境全血采集的有条件批准。最终的PRIME研究数据库预计将在九月中旬锁定，出版目标为春季怀孕会议。管理层正在执行各种成本有效的项目，以教育医生和患者关于他们的PreTRM®测试，包括与医疗专业平台的合作和多渠道营销策略。公司继续专注于建立证据组合和制定护理指南，以推动采用和营业收入增长。
Sera Prognostics报告2024年第二季度营业收入为24,000美元，较2023年第二季度的123,000美元下降。公司实现了营业费用减少20%，降至930万，导致净亏损收窄至830万，同比相比于1050万。研究与开发费用增加19%，达到440万，而销售、一般及行政费用减少38%，降至490万。公司强调最近的成就，包括正面结果的AVERt PRETERm试验报告以及来自纽约州的环境全血采集的有条件批准。最终的PRIME研究数据库预计将在九月中旬锁定，出版目标为春季怀孕会议。管理层正在执行各种成本有效的项目，以教育医生和患者关于他们的PreTRM®测试，包括与医疗专业平台的合作和多渠道营销策略。公司继续专注于建立证据组合和制定护理指南，以推动采用和营业收入增长。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间